Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-08T10:55:25.260Z Has data issue: false hasContentIssue false

Chapter 22 - Prophylaxis for deep venous thrombosis and pulmonary embolism in surgery

from Section 6 - Hematology

Published online by Cambridge University Press:  05 September 2013

By
Taki Galanis  and
Geno J. Merli
Edited by
Michael F. Lubin ,
Thomas F. Dodson  and
Neil H. Winawer
Michael F. Lubin
Affiliation:
Emory University, Atlanta
Thomas F. Dodson
Affiliation:
Emory University, Atlanta
Neil H. Winawer
Affiliation:
Emory University, Atlanta
Get access

Summary

Introduction

Venous thrombosis is a major cause of disability and death in all patient populations. Autopsy studies of hospitalized patients have demonstrated that massive pulmonary embolism (PE) is the cause of death in 5–10% of all hospital deaths and have suggested that two-thirds of all clinically important venous emboli are never recognized during life [1,2]. In a large multi-center study, 30,827 surgical patients were evaluated with respect to venous thromboembolism (VTE) risk and appropriate prophylaxis as recommended by the American College of Chest Physician (ACCP). This study showed that 19,842 surgical patients were considered at risk for VTE but only 11,613 (58.5%) received appropriate ACCP-recommended VTE prophylaxis [3]. More recently, the Surgical Care Improvement Project selected the application of VTE prophylaxis as a nationally reported metric for preventing VTE [4]. The purpose of this chapter is to review the pathophysiology of perioperative deep vein thrombosis (DVT), assess preoperative VTE risk and review the modalities of prophylaxis for preventing postoperative VTE in surgical patients.

Pathophysiology

The pathophysiologic changes of stasis, intimal injury, and hypercoagulability predispose surgical patients to the development of DVT or PE. The supine position on the operating room table, the anatomic position of the extremities for some surgical procedures, and the effect of anesthesia all contribute to stasis during surgery. Venographic contrast studies have shown that the supine position on the operating table decreases venous return [5,6]. In orthopedic, gynecologic, and urologic surgeries, the anatomic position of the body that provides the best surgical access to the operative site impairs adequate venous drainage during the procedure [7]. For example, in total hip replacement and hip fracture repair, the flexion and adduction of the hip that is required for better anatomic access to the surgical field has been shown to impair venous return [7]. Anesthesia causes peripheral venous vasodilation, which results in increased venous capacitance and decreased venous return during the operative procedure [8–10].

Type
Chapter
Information
Medical Management of the Surgical Patient
A Textbook of Perioperative Medicine
 , pp. 234 - 251
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carter, C, Gent, M.The epidemiology of venous thrombosis. In Colman, R, Hirsh, J, Marder, V, Salzman, E, eds. Hemostasis and Thrombosis. Philadelphia, PA: JB Lippincott; 1982, pp. 805–19.Google Scholar
Dismuke, S, Wagner, E.Pulmonary embolism as a cause of death: the changing mortality in hospitalized patients. J Am Med Assoc 1986; 255: 2039–42.CrossRefGoogle ScholarPubMed
Cohen, A, Tapson, V, Bergmann, J et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE Study): a multi-national cross sectional study. Lancet 2008; 371: 387–94.CrossRefGoogle Scholar
Surgical Care Improvement Project. Joint Commission website: .
Nicolaides, A, Kakkar, V, Renney, J.Soleal sinuses and stasis. Br J Surg 1970; 57: 307.Google Scholar
Nicolaides, A, Kakkar, V, Field, E et al. Venous stasis and deep vein thrombosis. Br J Surg 1972; 59: 713–16.CrossRefGoogle ScholarPubMed
Stamatakis, J, Kakkar, V, Sagar, S et al. Femoral vein thrombosis and total hip replacement. Br Med J 1977; 112: 223–5.CrossRefGoogle Scholar
Clark, C, Cotton, L.Blood flow in deep veins of the legs: recording technique and evaluation of method to increase flow during operation. Br J Surg 1968; 55: 211–14.CrossRefGoogle ScholarPubMed
Lindstrom, B, Ahlman, H, Honsson, O et al. Blood flow in the calves during surgery. Acta Chir Scand 1977; 143: 335–9.Google ScholarPubMed
Linstrom, B, Ahlman, H, Jonsson, O et al. Influence of anesthesia on blood flow to the calves during surgery. Acta Anaesthesiol Scand 1984; 28: 201–3.CrossRefGoogle Scholar
Johnson, R, Carmichael, J, Almond, H et al. Deep vein thrombosis following Charneley arthroplasty. Clin Orthop 1978; 132: 24–30.Google Scholar
Planes, A, Vochelle, N, Fagola, M.Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg 1990; 72B: 9–13.CrossRefGoogle Scholar
Comerota, A, Stewart, G, Alburger, P et al. Operative venodilation: a previously unsuspected factor in the cause of postoperative deep vein thrombosis. Surgery 1989; 106: 301–9.Google ScholarPubMed
Schaub, P, Lynch, P, Stewart, G.The response of canine veins to three types of abdominal surgery: a scanning and transmission electron microscope study. Surgery 1978; 83: 411–22.Google Scholar
Stewart, G, Schaub, R, Niewiarowske, S.Products of tissue injury: their induction of venous endothelial damage and blood cell adhesion in the dog. Arch Pathol Lab Med 1980; 104: 409–13.Google ScholarPubMed
Stewart, G, Alburger, P, Stone, E et al. Total hip replacement induces injury to remote veins in a canine model. J Bone Joint Surg 1983; 65A: 97–102.CrossRefGoogle Scholar
Gitel, S, Salvanti, E, Wessler, S et al. The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis. J Bone Joint Surg 1979; 61A: 653–6.CrossRefGoogle Scholar
Eriksson, B, Eriksson, E, Wessler, S et al. Thrombosis after hip replacement: relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159–63.CrossRefGoogle ScholarPubMed
Kluft, C, Verheijen, J, Jie, A et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605–10.CrossRefGoogle ScholarPubMed
D'Angelo, A, Kluft, C, Verheijen, J et al. Fibrinolytic shut down after surgery:impairment of the balance between tissue plasminogen activator and its specific inhibitors. Eur J Clin Invest 1985; 15: 308–12.CrossRefGoogle Scholar
Geerts, WH, Bergqvist, D, Pineo, GF et al. Prevention of venous thromboembolism. Chest 2008; 133: S381–453.CrossRefGoogle ScholarPubMed
Caprini, J.Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010; 199: S3–10.CrossRefGoogle ScholarPubMed
Bahl, V, Hu, HM, Henke, PK et al. A valid study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010; 2: 344–50.CrossRefGoogle Scholar
Clagett, G, Reisch, J.Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227–40.CrossRefGoogle ScholarPubMed
Hirsh, J, Levine, M.Low molecular weight heparin. Blood 1992; 79: 1–17.Google ScholarPubMed
Weitz, J.Low molecular weight heparins. N Engl J Med 1997; 337: 688–98.CrossRefGoogle ScholarPubMed
Samama, M.Synthetic direct and indirect factor Xa inhibitors. Thrombosis Res 2002; 106: 267–73.CrossRefGoogle ScholarPubMed
Johanson, N, Lachiewicz, PF, Lieberman, JR et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroscopy. J Am Acad Ortho Surg 2009; 17: 183–96.CrossRefGoogle ScholarPubMed
Mismetti, P, Laporte, S, Zufferey, P et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta analysis. J Thromb Haemost 2004; 2: 1058–70.CrossRefGoogle ScholarPubMed
Caprini, J, Scurr, J, Hasty, J.Role of compression modalities in a prophylactic program for deep vein thrombosis. Semin Thromb Hemost 1988; 14: 77–87.Google Scholar
Gardner, A, Fox, R.The venous pump of the human foot: a preliminary report. Bristol Med Chir J 1983; 98: 109–14.Google ScholarPubMed
Fordyce, M, Ling, R.A venous foot pump reduces thrombosis after total hip replacement. J Bone Joint Surg 1992; 74B: 45–9.CrossRefGoogle Scholar
Wilson, N, Das, S, Kakkar, V et al. Thrombo-embolic prophylaxis in total knee replacement: evaluation of the A-V impulse system. J Bone Joint Surg 1992; 74B: 50–2.CrossRefGoogle Scholar
Colwell, C, Froimson, M, Mont, M et al. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low molecular weight heparin. J Bone Joint Surg Am 2010; 92: 527–35.CrossRefGoogle ScholarPubMed
Raghavan, N, Frost, CE, Yu, Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74–81.CrossRefGoogle Scholar
Jiang, X, Crain, EJ, Luettgen, JM et al. Apixaban, an oral direct factor Xa inhibitor, inhibitis human clot-bound factor Xa activity in vitro. Thromb Haemost 2009; 101: 780–2.Google Scholar
Luettgen, JM, Wang, Z, Seiffer, DA et al. Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants. J Thromb Haemost 2007; 5 (Suppl. 2): p-T-633.Google Scholar
Frost, C, Yu, Z, Moore, K et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 2007; 5: P-M-664.Google Scholar
Kubitza, D, Becka, M, Wensing, G et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939: an oral, direct Factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873–80.CrossRefGoogle ScholarPubMed
Kubitza, D, Becka, M, Voith, B et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412–21.CrossRefGoogle ScholarPubMed
Perzborn, E, Strassburger, J, Wilmen, A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939, an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514–21.CrossRefGoogle ScholarPubMed
Weinz, C, Schwartz, T, Kubitza, D et al. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056–64.CrossRefGoogle ScholarPubMed
Ufer, M.Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572–85.Google ScholarPubMed
Kubitza, D, Becka, M, Zuehlsdorf, M et al. Effects of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral direct Factor Xa inhibitor, in healthy subjects, J Clin Pharmacol 2006; 46: 549–58.CrossRefGoogle Scholar
Stangier, J, Rathgen, K, Stahle, H et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47–59.CrossRefGoogle ScholarPubMed
Stangier, J, Rathgen, K, Stahle, H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292–303.CrossRefGoogle ScholarPubMed
European Medicines Agency (EMEA). European public assessment report: Pradaxa. .
Stangier, J, Eriksson, BI, Dahl, OE et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555–63.CrossRefGoogle ScholarPubMed
Stangier, J, Rathgen, K, Stahle, H et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9: 59–68.CrossRefGoogle ScholarPubMed
Stangier, J, Stahle, H, Rathgen, K et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug (abstract). XXIst Congress of the International Society of Thrombosis and Haemostasis 2007; P-T-677. Available at: . Accessed 7/21/2011.
Stangier, J, Stahle, H, Rathgen, K et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin (abstract) XXIst Congress of the International Society of Thrombosis and Haemostasis 2007; P-W-672. Available at .
Van Ryn, J, Stangier, J, Naertter, S et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103(6): 1116–27.Google ScholarPubMed
Collins, R, Scrimogeour, A, Yusuf, S et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162–73.CrossRefGoogle ScholarPubMed
Mismetti, P, Laporte, S, Darmon, JY et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913–30.CrossRefGoogle ScholarPubMed
Agnelli, G, Bergqvist, D, Cohen, AT et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high risk abdominal surgery. Br J Surg 2005; 92: 1212–20.CrossRefGoogle ScholarPubMed
Soderdahl, DW, Henderson, SR, Hansberry, KL.A comparison of intermittent pneumatic compression of the calf and whole leg in preventing deep venous thrombosis in urologic surgery. J Urol 1997; 157: 1774–6.CrossRefGoogle Scholar
Nurmohamed, MT, van Riel, AM, Henkens, CM et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75: 233–8.Google ScholarPubMed
Agnelli, G, Piovella, F, Buoncristiani, P et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339: 80–5.CrossRefGoogle ScholarPubMed
Goldhaber, SZ, Dunn, K, Gerhard-Herman, M et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122: 1933–7.CrossRefGoogle ScholarPubMed
Collen, JF.Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest 2008; 134(2): 237–49.CrossRefGoogle ScholarPubMed
Oates-Whitehead, RM, D'Angelo, A, Mol, B.Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynecological surgery. Cochrane Database Syst Rev 2003; 4: CD003679.Google Scholar
ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomized multicenter trial with venographic assessment Br J Surg 1997; 84: 1099–103.CrossRef
Baykal, C, Al, A, Demirtas, E et al. Comparison of enoxaparin and standard heparin in gynecologic oncologic surgery: a randomized prospective double blind clinical study. Eur J Gynaec Oncol 2001; 22: 127–30.Google Scholar
Fricker, JP, Vergnes, Y, Schach, R et al. Low dose heparin versus low molecular weight heparin (Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988; 18: 561–7.CrossRefGoogle ScholarPubMed
Heilmann, L, von Templehoff, GF, Kirkpatrick, C et al. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow up. Clin Appl Thromb Hemost 1998; 4: 268–73.CrossRefGoogle Scholar
Bergqvist, D, Agnelli, G, Cohen, AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–80.CrossRefGoogle ScholarPubMed
Eriksson, BI, Lassen, MR, the PENTassaccharide in HIpFRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multi-center, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337–42.CrossRefGoogle Scholar
Lassen, MR, Raskob, GE, Gallus, A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Eng J Med 2009; 361: 594–604.CrossRefGoogle ScholarPubMed
Lassen, MR, Raskob, GE, Gallus, A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807–15.CrossRefGoogle ScholarPubMed
Lassen, MR, Gallus, A, Raskob, GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487–98.CrossRefGoogle ScholarPubMed
Turpie, AG, Fisher, WD, Bauer, KA et al. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479–86.CrossRefGoogle ScholarPubMed
Eriksson, BI, Borris, LC, Dahl, OE et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374–81.CrossRefGoogle Scholar
Eriksson, BI, Borris, L, Dahl, OE et al. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121–8.CrossRefGoogle ScholarPubMed
Eriksson, BI, Borris, LC, Friedman, RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765–75.CrossRefGoogle ScholarPubMed
Lassen, MR, Ageno, W, Borris, LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–86.CrossRefGoogle ScholarPubMed
Kakkar, AK, Brenner, B, Dahl, OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31–9.CrossRefGoogle ScholarPubMed
Turpie, AG, Lassen, MR, Davidson, BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673–80.CrossRefGoogle ScholarPubMed
Ginsberg, JS, Davidson, BL, Comp, PC et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1–9.Google ScholarPubMed
Eriksson, BI, Dahl, OE, Rosencher, N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178–85.CrossRefGoogle ScholarPubMed
Eriksson, BI, Dahl, OE, Rosencher, N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949–56.CrossRefGoogle ScholarPubMed
Eriksson, BI, Dahl, OE, Huo, MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost 2011; 105(4): 721–9.Google Scholar
Bergqvist, D, Agnelli, G, Cohen, AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–80.CrossRefGoogle ScholarPubMed
Rasmussen, MS, Jorgensen, LM, Wille-Jorgensen, P et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open label study. J Thromb Haemost 2006; 4: 2384–90.CrossRefGoogle ScholarPubMed
Planes, A, Vochelle, N, Darmon, J et al. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996; 348: 224–8.CrossRefGoogle ScholarPubMed
Bergqvist, D, Benoni, G, Bjorgell, O et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696–700.CrossRefGoogle ScholarPubMed
Eikelboom, JW, Quinlan, DJ, Douketis, JD.Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet 2001; 358: 9–15.CrossRefGoogle ScholarPubMed
Douketis, JD, Eikelboom, JW, Quinlan, DJ et al. Short duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162: 1465–71.CrossRefGoogle ScholarPubMed
Cohen, AT, Bailey, CS, Alikhan, R et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001; 85: 940–1.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×